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Abstract
Background Oldest old patients aged 85 years and over are at risk of experiencing potentially inappropriate medications 
(PIMs) and potential prescribing omissions (PPOs) across transitions of care. Geriatricians also face enormous challenges 
in prescribing medications for these patients.
Methods A mixed-methods, sequential explanatory design was undertaken of electronic medical records and semi-structured 
interviews with geriatricians at a public teaching hospital. Data were collected at four time points using the Screening Tool 
of Older Persons’ potentially inappropriate Prescriptions (STOPP) and Screening Tool to Alert doctors to the Right Treat-
ment (START).
Results Of 249 patients, the prevalence of at least 1 PIM varied between 36.9 and 51.0%, while the prevalence of at least 1 
PPO varied between 36.9 and 44.6%. The most common PIM was use of proton pump inhibitors while the most common PPO 
was omission of vitamin D supplements in housebound patients or patients experiencing falls. Poisson regression analysis 
showed that PIMs were significantly associated with use of mobility aids, 1.430 (95% CI 1.109–1.843, p = 0.006), and number 
of medications prescribed at admission, 1.083 (95% CI 1.058–1.108, p < 0.001). PPOs were significantly associated with 
comorbidities, 1.172 (95% CI 1.073–1.280, p < 0.001), medications prescribed at admission, 0.989 (95% CI 0.978–0.999, 
p = 0.035), and length of stay, 1.004 (95% CI 1.002–1.006, p < 0.001). Geriatrician interviews (N = 9) revealed medication-
related, health professional-related and patient-related challenges with managing medications.
Conclusions Inappropriate prescribing is common in oldest old patients. Greater attention is needed on actively de-prescrib-
ing medications that are not beneficial and commencing medications that would be advantageous. Tailored strategies for 
improving prescribing practices are needed.
Keywords Oldest old · Transition · Inappropriate medication · Prescribing · Potentially inappropriate medication · Potential 
prescribing omission
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Introduction
Globally, the population is ageing. The number and propor-
tion of oldest old people, who are defined as individuals aged 
85 years and over, are increasing more rapidly than those in 
other age groups [1]. Oldest old people comprise about 2% of 
the population in the United States, while in 2030, this number 
is projected to increase to 2.5% and 3.7% in 2040 [2]. Old-
est old patients often present with several comorbidities that 
require the use of multiple medications.
Inappropriate medication use involves prescribing poten-
tially inappropriate medications (PIMs) and potential prescrib-
ing omissions (PPOs). In relation to PIMs, the risks of using 
particular medications outweigh their benefits, especially if 
there are safer and more effective options. With respect to 
PPOs, these are omitted medications that have a therapeutic 
use in the absence of contraindications [3, 4]. Inappropri-
ate prescribing can cause an increase in adverse drug events 
(ADEs), which are situations leading to patient harm with 
respect to an increase in morbidity, mortality and health care 
costs [5, 6]. With an ageing population, inappropriate prescrib-
ing is an international health care problem [7].
Screening tools for inappropriate prescribing have been for-
mulated to assist clinicians in providing efficient and appropri-
ate prescribing practices, as well as in reducing the prevalence 
of preventable ADEs [4, 8]. The STOPP (Screening Tool of 
Older Persons’ potentially inappropriate Prescriptions) and 
START (Screening Tool to Alert doctors to the Right Treat-
ment) criteria were developed in Ireland in 2003 to identify 
PIMs and PPOs, respectively. The STOPP and START were 
later validated by a Delphi consensus in 2006 [9]. Version Two 
of the criteria was released in 2014, comprising 80 STOPP 
and 32 START criteria [10]. The STOPP and START criteria 
have been applied in various studies and have been shown to 
be effective screening tools [11, 12]. Despite their potential 
benefits and utility, little work has been undertaken using these 
criteria amongst hospitalised oldest old patients.
The aims of this paper are: to examine the prevalence of 
inappropriate medication use in oldest old patients across 
transitions of care using the STOPP and START criteria; to 
determine which medication categories have a high prevalence 
of inappropriate medication use in oldest old patients; and to 
examine challenges associated with medication prescribing in 
oldest old patients from the perspectives of geriatricians.
Methods
Study design, setting and participants
A mixed-methods, sequential explanatory design was used, 
involving a retrospective clinical audit of electronic medical 
records and semi-structured interviews. The study was 
undertaken at an Australian public, teaching hospital with 
two sites, comprising 570 beds. This hospital served over 
550,000 people living in the northern and western regions 
of the state of Victoria. At this hospital, doctors were taught 
about the importance of deprescribing in older patients, and 
also about the process of doing therapeutic reconciliation.
For the audit, the patient sample was randomly selected 
by an independent researcher who extracted data such as age, 
gender, admission dates, and primary diagnostic codes. The 
inclusion criteria were patients aged 85 years and over, who 
presented to the emergency department (ED) of the study 
hospital, and were admitted to the hospital between Janu-
ary 1st 2016 and December 31st 2016 with at least 1 medi-
cation on presentation. The exclusion criteria comprised 
patients who were admitted to the intensive care unit, died 
before discharge, were palliated prior to discharge, were dis-
charged to other hospitals or private rehabilitation following 
ED presentation, had incomplete or unobtainable records, 
had duplicate admission dates in the electronic system, 
declined medications on ED presentation or were a tourist 
and therefore medication prescriptions were not reflective 
of the local situation. There were 1458 potentially eligible 
patients admitted to the emergency department across the 
1-year audit period. Using a random numbers table, medical 
records were randomly sampled to determine the eligibility 
for inclusion and till the required sample was obtained.
Using purposive sampling by considering gender and 
years of working experience, interviews were conducted 
with geriatricians who worked in the geriatric evaluation 
and management or general medical units of the hospital.
Procedure
Demographic and medication information were obtained 
from the ED notes, admission notes, discharge summaries 
relating to patients’ discharge from acute and subacute 
settings, medication charts and progress notes. Pathology 
results and observation charts were also perused to obtain 
details of adverse clinical outcomes experienced by older 
patients. Data were obtained for four different time points 
during oldest old patients’ hospital stay. These time points 
were as follows: time point 1: medications on presentation 
to ED; time point 2: medications on admission to acute care; 
time point 3: medications on discharge from acute care to 
subacute care; and time point 4: medications on discharge 
from acute care directly to home/residential care or on dis-
charge from subacute care to home/residential care. It is 
important to note that not all patients were discharged from 
acute care to subacute care.
Data were documented in an Excel spreadsheet (version 
2010), which was directly imported into IBM SPSS (ver-
sion 25). Medications prescribed were noted for each patient 
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at each of the four time points. The STOPP/START crite-
ria (version 2) were applied and the PIMs and PPOs were 
documented for each time point. For patients who had an 
identified PIM, vital sign observations, physical examina-
tions, pathology tests and imaging results were examined to 
identify adverse clinical outcomes as possible clinical mani-
festations occurring during the patients’ stay. The Adverse 
Clinical Outcomes Tool was used to record potential adverse 
clinical outcomes which were developed from the STOPP 
criteria. Thus, in identifying adverse clinical outcomes, 
these related to medications that were prescribed and not 
withdrawn.
Data were collected on patient age, gender, use of walk-
ing aids, presence of documented allergy, presence of docu-
mented dementia, and presence of documented faecal or uri-
nary incontinence. The Charlson comorbidity index (CCI) 
was manually calculated using an online calculator [13]. 
Transition points were defined as the number of changes in 
the location of a patient during hospitalisation. Change in 
discharge destination was calculated and defined as a change 
in the place of dwelling due to higher care requirements, 
such as moving from home to a residential care facility. 
Communication barriers were identified and defined by the 
presence of confusion from delirium or dementia, aphasia, 
dysphasia, dysarthria, hearing impairment, or an inability 
to communicate in English without an interpreter. The total 
length of hospital stay was calculated as the length of stay in 
acute care and subacute care. Functional Status was defined 
as patients requiring assistance with activities of daily liv-
ing (ADL) in each of the domains (personal, domestic and 
community). Personal ADLs involved showering, dressing, 
toileting, eating, and grooming. Domestic ADLs involved 
completing household tasks like cooking and cleaning. Com-
munity ADLs comprised driving and shopping. If patients 
required assistance in any of these areas, they were allocated 
a score of 1 and a score of 0 if they were independent. The 
presence of a falls history was defined as having clear docu-
mentation of being a recurrent faller or having been referred 
to the falls clinic. Polypharmacy and excessive polyphar-
macy were defined arbitrarily as ≥ 5 and ≥ 10 medications.
In organising structured interviews with geriatricians, the 
questions posed included the barriers to safe prescribing in 
older patients, and challenges they experienced in ceasing 
or commencing medications.
Data analysis
Descriptive statistical analysis was performed, with cat-
egorical variables analysed using summary counts and 
percentages. For continuous variables with skewed dis-
tributions, medians and inter-quartile ranges were calcu-
lated. The following explanatory variables were examined 
at the univariate level to determine their effects on PIMs or 
PPOs: age, use of aids, documented allergy, documented 
dementia, history of falls, incontinence, personal ADLs, 
domestic ADLs, community ADLs, communication bar-
rier, comorbid conditions, number of medications pre-
scribed on admission, total length of stay, and age. Uni-
variate associations with p values of ≤ 0.25 were included 
in the Poisson regression modelling. Poisson regression 
modelling was performed using the number of counts of 
PIMs or PPOs as the dependent (outcome) variable and 
explanatory variables. The level of significance utilised 
was alpha = 0.05.
Using a prevalence rate for PIMs of 54% found in the 
previous Australian study conducted by Manias et al. [14], 
and based on a desired 95% confidence interval width of 
0.125, the sample size was calculated to be 245 patients. 
Therefore, data were required to be collected on about 245 
patient medical records.
Audio-recorded interviews of geriatricians were tran-
scribed verbatim. Thematic analysis was undertaken, 
which involved each author independently reading and 
rereading the data transcripts many times, identifying ini-




Data on 249 randomly selected medical records were col-
lected (Fig. 1). The demographic characteristics are summa-
rised in Table 1. The median age of patients was 88.5 years, 
with the oldest patient being 103 years old. The most com-
mon diagnosis of admitted patients to acute care was conges-
tive cardiac failure, followed by sepsis, pelvic or femur frac-
ture and cerebral infarction. There were 90 (36.7%) patients 
who had acute kidney injury on admission.
On presentation to ED, a total of 2,425 medications were 
prescribed to the entire study population with a median 
number of 10 medications (range 1–20). On admission to 
the acute unit, a total of 2254 medications were prescribed 
with a median number of 9 medications (range 2–10). On 
admission to the subacute unit, a total of 1,062 medications 
were prescribed to 108 patients admitted to the subacute 
unit with a median number of 10 medications (range 3–21). 
On discharge, a total of 2,391 medications were prescribed 
with a median of 9 medications (range 1–21). Polypharmacy 
increased slightly from 90.2% on presentation to ED, to 
95.1% at discharge while excessive polypharmacy margin-
ally dropped from 50.8% on presentation to ED, to 48.8% 
at discharge. All patients had changes to their medications 
during hospitalisation.
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Characteristics of potentially inappropriate 
medications
Characteristics of potentially inappropriate medications 
are summarised in Table 2. There were 476 occurrences 
in the whole sample. The total numbers of PIMs at the 
four different time points were 195, 123, 51 and 107, 
respectively. The prevalence of having at least 1 PIM at 
the different time points was 51.0%, 37.3%, 40.4% and 
36.9%, respectively. The most common PIMs were the 
use of proton pump inhibitors for uncomplicated peptic 
ulcer disease, followed by use of benzodiazepines, and 
medications prescribed without an evidence-based clinical 
indication. The common medications that were prescribed 
without any clear clinical indication were aspirin, frusem-
ide, spironolactone and amitriptyline.
Characteristics of potential prescribing omissions
For the purpose of PPO characteristics, results reported 
here exclude the prevalence of vaccination omission as 
information about vaccinations tended not to be collected 
by the hospital. For information about PPOs relating to 
vaccination—omission of documentation about having a 
pneumococcal vaccine at least once after the age of 65, and 
omission of a seasonal trivalent influenza vaccine annu-
ally—refer to results in the supplementary material. The 
total numbers of PPOs at the four different time points 
were 158, 153, 66 and 125 respectively. There were 502 
occurrences in the whole sample. The prevalence of hav-
ing at least 1 PPO at the four different time points was 
44.6%, 43.8%, 41.8% and 36.9%, respectively. The most 
common PPOs were omission of Vitamin D supplements 
Fig. 1  Flow chart for access of 
sample Total population of 1,458 potentially 
eligible patients across the one-year 
audit period
Final sample for inclusion 
(N=249)
Ineligible patients (n=198) based 
on the ineligibility criteria:
1. Patients not presenting to 
the emergency 
department, or patients 
admitted to intensive care 
unit or patients not having 
medications in ED 
presentation (n=32)
2. Died before discharge 
(n=42)
3. Patients palliated (n=23)
4. Discharged to other 
hospitals or private 
rehabilitation following 
ED presentation (n=34)
5. Incomplete or 
unobtainable records 
(n=13)
6. Patients with duplicate 
admission dates (n=51)
7. Patients declining 
medications on ED 
presentation (n=2)
8. Patient was a tourist and 
therefore medication 
practices not reflecting 
local situation (n=1)
Random access to medical records 
using random numbers table till final 
sample obtained
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in housebound patients or patients experiencing falls, fol-
lowed by the omission of angiotensin converting enzyme 
(ACE) inhibitors in patients with systolic heart failure or 
ischaemic heart disease. The next most common PPOs 
involved the omission of beta-blockers with ischaemic 
heart disease (Table 3).
Adverse clinical outcomes
The total number of adverse clinical outcomes across the 
sample at the 4 different time points was 71, 42, 13 and 
19 respectively. The most common adverse clinical out-
comes were associated with prolonged use of a proton pump 
inhibitor, benzodiazepine, neuroleptic medication and non-
steroidal anti-inflammatory drugs. As time progressed dur-
ing the patients’ hospitalisation, the prevalence of adverse 
clinical outcomes decreased from admission to discharge 
(Table 4).
Poisson regression results
Poisson regression analyses were undertaken to predict the 
incident count for PIMs and PPOs in relation to explana-
tory variables (Table 5). Use of mobility aids and a higher 
number of medications on admission were associated with a 
higher incident count for PIMs. A higher comorbidity num-
ber and a higher length of hospital stay were associated with 
an increased incident count for PPOs. A higher number of 
medications on admission was associated with a reduced 
incidence rate of PPOs.
Table 1  Demographic characteristics (N = 249)
Variable n (%)
Age, years (n, %)
 85–90 173 (69.5%)
 91–95 62 (24.9%)
 ≥ 96 14 (5.6%)
Age, years




Place of living (n, %)
 Home, with someone 143 (57.4%)
 Home, alone 79 (31.7%)
 Residential care 27 (10.8%)
Use of gait aids (n, %)
 4 wheel frame (4WF) 117 (47.0%)
 Single  point stick (SPS) 44 (17.7%)
 2 wheel frame, bedbound, crutches, hoist, wheelchair 7 (2.8%)
 Not using aids 81 (32.5%)
Functional status (n, %)
 Requiring assistance in at least one area for personal 
activities of daily living (ADL)
81 (32.5%)
 Requiring assistance in at least one domestic ADL 177 (71.1%)
 Requiring assistance in at least one community ADL 190 (76.3%)
Communication barrier
 Non English-speaking background 72 (28.9%)
 Confusion from delirium or dementia 22 (8.8%)
 Aphasia/dysphasia 3 (1.2%)
 No communication barrier 149 (59.8%)
Sensory deficits
 Hearing difficulties 45 (18.1%)
 Vision difficulties 66 (26.5%)
 Both 23 (9.2%)
Language other than English
 Italian 51 (20.5%)
 Greek 21 (8.4%)
 Other (Polish, Vietnamese, Cantonese, Ukrain-
ian, Mandarin, Dutch, Czechoslovakian, Filipino, 




 Median (Q25 Q75) 7 (5;8)




 Urinary incontinence 36 (14.5%)
 Faecal incontinence 1 (0.4%)
 Double incontinence 11 (4.4%)
Length of stay in days (median, Q25;Q75)
 Acute 8 (6;12)
Table 1  (continued)
Variable n (%)
 Subacute geriatric evaluation and management unit 20 (13;32)
 Subacute transitional care practice 34 (14;41)
 Total 13 (7;33)
Transition points
 Median (Q25;Q75) 3 (3;4)








 Discharge to same destination as admission 212 (85.1%)
 Change to higher level of care 37 (14.9%)
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Table 2  Frequency of incidents across four snapshots of time for the Screening Tool of Older Persons’ potentially inappropriate Prescriptions 
(STOPP)
Criteria Snapshots of 
time
Total
1 2 3 4
Section A: indication of medication
 1. Any drug prescribed without an evidence-based clinical indication 24 17 6 10 57
 3. Any duplicate drug class prescription, e.g. two concurrent non steroidal anti-inflammatory drugs (NSAIDs), 
selective serotonin reuptake inhibitors (SSRIs), loop diuretics, angiotensin converting enzyme (ACE) inhibitors, 
anticoagulants (optimisation of monotherapy within a single drug class should be observed prior to considering a 
new agent)
5 2 7
Section B: cardiovascular system
 1. Digoxin for heart failure with normal systolic ventricular function (no clear evidence of benefit) 2 2 1 2 7
 4. Beta-blocker with bradycardia (< 50/min), type II heart block or complete heart block (risk of complete heart 
block, asystole)
2 1 0 0 3
 5. Amiodarone as first-line antiarrhythmic therapy in supraventricular tachyarrhythmias (higher risk of side-effects 
than beta-blockers, digoxin, verapamil or diltiazem)
1 1 0 0 2
 6. Loop diuretic as first-line treatment for hypertension (safer, more effective alternatives available) 5 3 1 6 15
 7. Loop diuretic for dependent ankle oedema without clinical, biochemical evidence or radiological evidence of 
heart failure, liver failure, nephrotic syndrome or renal failure (leg elevation and /or compression hosiery usually 
more appropriate)
1 1 0 1 3
 8. Thiazide diuretic with current significant hypokalaemia (i.e. serum K + < 3.0 mmol/l), hyponatraemia (i.e. 
serum Na + < 130 mmol/l) hypercalcaemia (i.e. corrected serum calcium > 2.65 mmol/l) or with a history of gout 
(hypokalaemia, hyponatraemia, hypercalcaemia and gout can be precipitated by thiazide diuretic)
5 1 0 1 7
 9. Loop diuretic for treatment of hypertension with concurrent urinary incontinence (may exacerbate incontinence) 1 1 0 1 3
 11. ACE inhibitors or Angiotensin Receptor Blockers in patients with hyperkalaemia 7 4 1 1 13
 12. Aldosterone antagonists (e.g. spironolactone, eplerenone) with concurrent potassium-conserving drugs (e.g. 
ACE inhibitors, angiotensin II receptor blockers (ARBs), amiloride, triamterene) without monitoring of serum 
potassium (risk of dangerous hyperkalaemia i.e. > 6.0 mmol/l – serum K should be monitored regularly, i.e. at 
least every 6 months)
2 0 0 0 2
Section C: antiplatelet/anticoagulant drugs
 2. Aspirin with a past history of peptic ulcer disease without concomitant proton pump inhbitor (PPI) (risk of recur-
rent peptic ulcer)
1 1 0 0 2
 4. Aspirin plus clopidogrel as secondary stroke prevention, unless the patient has a coronary stent(s) inserted in 
the previous 12 months or concurrent acute coronary syndrome or has a high-grade symptomatic carotid arterial 
stenosis (no evidence of added benefit over clopidogrel monotherapy)
1 2 0 0 3
 5. Aspirin in combination with vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors in patients 
with chronic atrial fibrillation (no added benefit from aspirin)
1 1 0 1 3
 6. Antiplatelet agents with vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors in patients with 
stable coronary, cerebrovascular or peripheral arterial disease (No added benefit from dual therapy)
1 1 0 1 3
 8. Vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors for first deep venous thrombosis without 
continuing provoking risk factors (e.g. thrombophilia) for > 6 months, (no proven added benefit)
0 0 1 0 1
 10. NSAID and vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors in combination (risk of major 
gastrointestinal bleeding)
7 6 1 8 22
 11. NSAID with concurrent antiplatelet agent(s) without PPI prophylaxis (increased risk of peptic ulcer disease) 2 3 0 1 6
Section D: central nervous system and psychotropic drugs
 2. Initiation of tricyclic antidepressants (TCAs) as first-line antidepressant treatment (higher risk of adverse drug 
reactions with TCAs than with SSRIs or serotonin and noradrenaline reuptake inhibitors (SNRIs))
4 1 1 1 7
 5. Benzodiazepines for ≥ 4 weeks (no indication for longer treatment; risk of prolonged sedation, confusion, 
impaired balance, falls, road traffic accidents; all benzodiazepines should be withdrawn gradually if taken for more 
than 4 weeks as there is a risk of causing a benzodiazepine withdrawal syndrome if stopped abruptly)
2 0 0 0 2
 7. Anticholinergics/antimuscarinics to treat extrapyramidal side-effects of neuroleptic medications (risk of anticho-
linergic toxicity)
1 1 0 0 2
 8. Anticholinergics/antimuscarinics in patients with delirium or dementia (risk of exacerbation of cognitive impair-
ment)
2 1 1 1 5
 14. First-generation antihistamines (safer, less toxic antihistamines now widely available) 1 0 0 0 1
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Qualitative interview results
Interviews were undertaken with five female and four male 
geriatricians. Identified themes related to challenges in 
prescribing medications, challenges confronting geriatri-
cians, and challenges faced by patients (see supplementary 
material).
Challenges in prescribing medications
Geriatricians referred to challenges in prescribing medica-
tions. Time constraints created difficulties in seeking the rel-
evant medication history from specialists and general prac-
titioners (GPs). Oldest old patients came to hospital from 
residential aged care where there were many GPs managing 
Table 2  (continued)
Criteria Snapshots of 
time
Total
1 2 3 4
Section E: renal system
 1. Digoxin at a long-term dose greater than 125 µg/day if estimated glomerular filtration rate (eGFR) < 30 ml/
min/1.73 m2 (risk of digoxin toxicity if plasma levels not measured)
1 0 0 0 1
 2. Direct thrombin inhibitors (e.g. dabigatran) if eGFR < 30 ml/min/1.73 m2 (risk of bleeding) 1 1 0 0 2
 6. Metformin if eGFR < 30 ml/min/1.73 m2 (risk of lactic acidosis) 3 3 0 1 7
Section F: gastrointestinal system
 1. Prochlorperazine or metoclopramide with Parkinsonism (risk of exacerbating Parkinsonian symptoms) 1 0 0 0 1
 2. PPI for uncomplicated peptic ulcer disease or erosive peptic oesophagitis at full therapeutic dosage for > 8 weeks 
(dose reduction or earlier discontinuation indicated)
52 43 21 40 156
 3. Drugs likely to cause constipation (e.g. antimuscarinic/anticholinergic drugs, oral iron, opioids, verapamil, alu-
minium antacids) in patients with chronic constipation where non-constipating alternatives are available (risk of 
exacerbation of constipation)
1 1 1 0 3
Section G: respiratory system
 1. Theophylline as monotherapy for chronic obstructive pulmonary disease (COPD) (safer, more effective alterna-
tive; risk of adverse effects due to narrow therapeutic index)
1 1 0 0 2
 3. Antimuscarinic bronchodilators (e.g. ipratropium, tiotropium) with a history of narrow-angle glaucoma (may 
exacerbate glaucoma) or bladder outflow obstruction (may cause urinary retention)
0 0 0 1 1
 5. Benzodiazepines with acute or chronic respiratory failure i.e. pO2 < 8.0 kPa ± pCO2 > 6.5 kPa (risk of exacerba-
tion of respiratory failure)
1 0 0 0 1
Section H: musculoskeletal system
 2. NSAID with severe hypertension (risk of exacerbation of hypertension) or severe heart failure (risk of exacerba-
tion of heart failure)
3 3 0 1 7
 5. Corticosteroids (other than periodic intra-articular injections for mono-articular pain) for osteoarthritis (risk of 
systemic corticosteroid side-effects)
1 1 0 0 2
 8. NSAID with concurrent corticosteroids without PPI prophylaxis (increased risk of peptic ulcer disease) 2 2 0 3 7
Section I: urogenital system
 1. Antimuscarinic drugs with dementia, or chronic cognitive impairment (risk of increased confusion, agitation) or 
narrow-angle glaucoma (risk of acute exacerbation of glaucoma), or chronic prostatism (risk of urinary retention)
0 0 0 1 1
Section J: endocrine system
Section K: drugs that predictably increase the risk of falls in older people
 1. Benzodiazepines (sedative, may cause reduced sensorium, impair balance) 32 10 5 13 60
 2. Neuroleptic drugs (may cause gait dyspraxia, Parkinsonism) 11 8 6 10 35
 3. Vasodilator drugs (e.g. alpha-1 receptor blockers, calcium channel blockers, long-acting nitrates, ACE inhibitors, 
angiotensin I receptor blockers) with persistent postural hypotension i.e. recurrent drop in systolic blood pres-
sure ≥ 20 mmHg (risk of syncope, falls)
1 1 1 0 3
Section L: analgesic drugs
 1. Use of oral or transdermal strong opioids (morphine, oxycodone, fentanyl, buprenorphine, diamorphine, metha-
done, tramadol, pethidine, pentazocine) as first-line therapy for mild pain (World Health Organization (WHO) 
analgesic ladder not observed)
2 1 2 0 5
 2. Use of regular (as distinct from pro re nata, as required (PRN) opioids without concomitant laxative (risk of 
severe constipation)
3 1 2 0 6
Section N: antimuscarinic/anticholinergic drug burden
1668 Aging Clinical and Experimental Research (2019) 31:1661–1673
1 3
Table 3  Frequency of incidents across four snapshots of time for the Screening Tool of Alert doctors to the Right Treatment (START)
Criteria Snapshots of time Total
1 2 3 4
Section A: cardiovascular system
 1. Vitamin K antagonists or direct thrombin inhibitors or factor Xa inhibitors in the presence of chronic atrial 
fibrillation
5 3 1 3 12
 2. Aspirin (75 mg–160 mg once daily) in the presence of chronic atrial fibrillation, where Vitamin K antagonists 
or direct thrombin inhibitors or factor Xa inhibitors are contraindicated
4 3 2 1 10
 3. Antiplatelet therapy (aspirin or clopidogrel or prasugrel or ticagrelor) with a documented history of coronary, 
cerebral or peripheral vascular disease
11 9 5 4 29
 4. Antihypertensive therapy where systolic blood pressure consistently > 160 mmHg and/or diastolic blood 
pressure consistently > 90 mmHg; if systolic blood pressure > 140 mmHg and /or diastolic blood pres-
sure > 90 mmHg, if diabetic
2 1 1 0 4
 5. Statin therapy with a documented history of coronary, cerebral or peripheral vascular disease, unless the 
patient’s status is end-of-life or age is > 85 years
2 1 1 2 6
 6. Angiotensin converting enzyme (ACE) inhibitor with systolic heart failure and/or documented coronary artery 
disease
25 25 10 27 87
 7. Beta-blocker with ischaemic heart disease 22 21 6 17 66
 8. Appropriate beta-blocker (bisoprolol, nebivolol, metoprolol or carvedilol) with stable systolic heart failure 1 1 0 1 3
Section B: respiratory system
 1. Regular inhaled beta-2 agonist or antimuscarinic bronchodilator (e.g. ipratropium, tiotropium) for mild-to-mod-
erate asthma or chronic obstructive pulmonary disease (COPD)
6 5 5 4 20
 2. Regular inhaled corticosteroid for moderate–severe asthma or COPD, where forced expiratory volume in 1 sec 
(FEV1) < 50% of predicted value and repeated exacerbations requiring treatment with oral corticosteroids
2 2 1 1 6
Section C: central nervous system and eyes
 2. Non-tricyclic antidepressant (TCA) drug in the presence of persistent major depressive symptoms 1 0 0 0 1
 3. Acetylcholinesterase inhibitor (e.g. donepezil, rivastigmine, galantamine) for mild–moderate Alzheimer’s 
dementia or Lewy Body dementia (rivastigmine)
4 5 1 5 15
 4. Topical prostaglandin, prostamide or beta-blocker for primary open-angle glaucoma 1 1 0 1 3
Section D: gastrointestinal system
 2. Fibre supplements (e.g. bran, ispaghula, methylcellulose, sterculia) for diverticulosis with a history of constipa-
tion
1 1 0 1 3
Section E: musculoskeletal system
 3. Vitamin D and calcium supplement in patients with known osteoporosis and/or previous fragility fracture(s) 
and/or (Bone Mineral Density T-scores more than − 2.5 in multiple sites)
5 6 5 6 22
 4. Bone anti-resorptive or anabolic therapy (e.g. bisphosphonate, strontium ranelate, teriparatide, denosumab) 
in patients with documented osteoporosis, where no pharmacological or clinical status contraindication exists 
(Bone Mineral Density T-scores -> 2.5 in multiple sites) and/or previous history of fragility fracture(s)
15 15 5 14 49
 5. Vitamin D supplement in older people who are housebound or experiencing falls or with osteopenia (Bone 
Mineral Density T-score is > -1.0 but < -2.5 in multiple sites)
44 50 22 37 153
 7. Folic acid supplement in patients taking methotrexate
Section F: endocrine system
 1. ACE inhibitor or angiotensin receptor blocker (if intolerant of ACE inhibitor) in diabetes with evidence of renal 
disease i.e. dipstick proteinuria or microalbuminuria (> 30 mg/24 h) with or without serum biochemical renal 
impairment
1 1 0 1 3
Section G: urogenital system
 1. Alpha-1 receptor blocker with symptomatic prostatism, where prostatectomy is not considered necessary 2 0 0 0 2
 2. 5-alpha reductase inhibitor with symptomatic prostatism, where prostatectomy is not considered necessary 2 1 0 0 3
Section H: analgesics
 1. High-potency opioids in moderate–severe pain, where paracetamol, non steroidal anti-inflammatory drugs 
(NSAIDs) or low-potency opioids are not appropriate to the pain severity or have been ineffective
0 0 1 0 1
 2. Laxatives in patients receiving opioids regularly 2 2 0 0 4
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them rather than a regular GP, leading to loss of information 
regarding reasons for prescribing.
Since oldest old patients were often excluded in research 
studies, geriatricians believed a lack of evidence-based med-
ication management existed in this population. Geriatricians 
had to extrapolate results from studies in younger patients. 
A dearth of data existed on the safety profile and efficacy of 
commonly used medications.
Difficulties arose from patients’ inability to afford cer-
tain medications. While geriatricians attempted to prescribe 
medications according to evidence, patients sometimes faced 
problems with accessing beneficial medications from a lack 
of government subsidisation.
The nature of adverse effects of certain medications, such 
as anticoagulants and insulin, meant that geriatricians had 
to carefully evaluate before commencing these medications. 
This caution sometimes led to delays in starting potentially 
beneficial medications.
Challenges in prescribing confronting geriatricians
Geriatricians referred to the differential knowledge about 
the oldest old sometimes contributed to inappropriate pre-
scribing. While aged care trainee doctors usually had good 
understanding of safe prescribing, geriatricians perceived 
that doctors from other specialities and junior doctors may 
have had gaps in prescribing knowledge. These knowledge 
gaps could have led to potentially toxic levels of medica-
tions and patients taking inappropriate medications over the 
long-term.
Table 4  Frequency of incidents across four snapshots of time for adverse clinical outcomes
Criteria Snapshots of 
time
Total
1 2 3 4
Beta-blocker with bradycardia (< 50/min), type II heart block or complete heart block (risk of complete heart block, asys-
tole)—Pulse < 50/min, type II heart block or complete heart block
2 1 0 0 3
Loop diuretic as first-line treatment for hypertension—hypokalaemia (K + < 3.5 mmol/L, hypomagnesaemia, dehydration 3 2 1 1 7
Thiazide diuretic with current significant hypokalaemia, hypercalcaemia or with a history of gout—serum 
K + < 3.5 mmol/L, serum Na + < 130 mmol/l, serum calcium > 2.65 mmol/l, active gout
5 3 0 2 10
Loop diuretic for treatment of hypertension with concurrent urinary incontinence—presence of urinary incontinence 3 3 1 3 10
ACE inhibitors or angiotensin receptor blockers in patients with hyperkalaemia—worsening hyperkalaemia 
(K + > 5 mmol/L)
3 2 0 0 5
Aldosterone antagonists (e.g. spironolactone, eplerenone) with concurrent potassium-conserving drugs—worsening hyper-
kalaemia (K + > 5 mmol/L)
2 0 0 0 2
Antiplatelet agents with vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors in patients with stable coro-
nary, cerebrovascular or peripheral arterial disease—abnormal clotting profile
2 2 0 1 5
Benzodiazepines for ≥ 4 weeks—sedation, confusion, impaired balance, and falls 4 1 1 0 6
Anticholinergics/antimuscarinics in patients with delirium or dementia—cognitive impairment 1 1 0 0 2
Digoxin at a long-term dose greater than 125 µg/day if estimated glomerular filtration rate (eGFR) < 30 ml/min/1.73 m2—
clinical manifestations of digoxin toxicity
1 1 0 1 3
Metformin if eGFR < 30 ml/min/1.73 m2—Muscle weakness, numbness in limbs, dyspnoea, dizziness, light-headedness, 
nausea, vomiting, gastrointestinal pain, bradycardia
3 2 0 0 5
Proton pump inhibitor (PPI) for > 8 weeks—Hypocalcaemia (normal: 2.1–2.6 mmol/L), hypomagnesemia (normal: 
0.75–1.25 mmol/L), Clostridium difficile infections, and pneumonia
14 12 5 5 36
Drugs likely to cause constipation (e.g. antimuscarinic/anticholinergic drugs—worsening constipation) 1 1 2 0 4
Antimuscarinic bronchodilators (e.g. ipratropium, tiotropium) with a history of narrow-angle glaucoma or bladder outflow 
obstruction—glaucoma, urinary retention
0 0 0 1 1
Benzodiazepines with acute or chronic respiratory failure—dyspnoea, confusion, reduced oxygen saturation 1 0 0 0 1
NSAID with severe hypertension—documented heart failure clinical manifestations 4 4 1 2 11
Corticosteroids other than periodic intra-articular injections—documented cataracts, high blood glucose levels, infections, 
fever, bleeding, frail skin
1 1 0 0 2
Benzodiazepine use—documented prolonged sedation, confusion, impaired balance, falls 14 2 0 1 17
Neuroleptic drug use—documented confusion, gait dyspraxia, prone to falls, hypotension (< 90/60 mmHg), documented 
extrapyramidal symptoms
6 3 0 2 11
Vasodilator drugs with persistent postural hypotension—drop in systolic blood pressure ≥ 20 mmHg in lying or sitting 
position, syncope, falls
1 1 2 0 4
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Patients were managed by multiple specialists who some-
times considered their area of expertise rather than patients 
as a whole. A lack of coordinated care existed between spe-
cialists, resulting in patients being prescribed many medi-
cations with an increased risk of drug interactions. Patients 
were also reluctant to discontinue medications prescribed 
by specialists.
Geriatricians stated that while disease management 
guidelines were useful, strict observation of guidelines 
could lead to polypharmacy. Guidelines needed to be tai-
lored to the oldest old, especially since guidelines were 
mostly based on younger populations. Strict adherence to 
guidelines could also lead to patients missing out on ben-
eficial medications.
Geriatricians had difficulties in completing timely medi-
cation reconciliation on hospital admission. Inadequate 
information was sometimes available about the type of medi-
cations, dosages and indications.
All geriatricians believed that patients needed to be 
actively involved in decisions and goals of care. Active 
involvement meant that patients’ wishes could be consid-
ered in consultations.
As the hospital used a paper-based approach in informa-
tion management, geriatricians stated there was a potential 
loss of information regarding medications. This situation 
increased the risk for medication errors and miscommuni-
cation, especially with patient movements between clinical 
settings.
Geriatricians believed that their medical colleagues were 
at times over-cautious about prescribing. These colleagues 
occasionally overestimated the risk of adverse effects, 
leading to patients missing out on potentially beneficial 
medications.
Challenges faced by patients
Geriatricians believed that patients were susceptible to 
adverse effects. Challenges existed in diversity in patterns 
and severity of patient illness.
Patients were reluctant to cease medications, especially 
those prescribed by specialists or general practitioners in 
private practice. This reluctance related to doctors previ-
ously informing patients that some medications had to 
be continued for life. Convincing patients otherwise, was 
challenging. Families of patients with dementia were also 
opposed to medication changes because of patients’ worsen-
ing cognition.
Table 5  Poisson regression 
analysis for predicting the count 
of potentially inappropriate 
medications (PIMs) and 
potential prescribing omissions 
(PPOs)
Explanatory variables examined at the univariate level were: age, use of aids, documented allergy, docu-
mented dementia, history of falls, incontinence, personal activities of daily living, domestic ADLs, com-
munity ADLs, communication barrier, comorbid conditions, number of medications prescribed on admis-
sion, total length of stay, and age. Only those variables that had univariate associations with p values of 
≤ 0.25 were included in Poisson regression modelling
Variable Exp(B) inci-
dent count
p Value 95% 
Confidence 
intervals
Potentially inappropriate medications (PIMs)
 Use of mobility aids 1.430 0.006 1.109, 1.843
 Documented allergy 0.953 0.618 0.789, 1.151
 History of falls 1.071 0.484 0.883, 1.299
 Incontinence 1.040 0.744 0.822, 1.316
 Dependence with personal activities of daily living 0.951 0.649 0.767, 1.180
 Dependence with domestic activities of daily living 1.054 0.751 0.763, 1.454
 Dependence with community activities of daily living 1.327 0.138 0.913, 1.927
 Number of medications on admission 1.083 < 0.0001 1.058, 1.108
 Total length of stay 0.998 0.451 0.994, 1.003
Potential prescribing omissions (PPOs)
 Dementia 1.019 0.723 0.916, 1.134
 History of falls 1.096 0.051 1.000, 1.202
 Incontinence 1.088 0.147 0.971, 1.219
 Dependence with domestic activities of daily living 0.975 0.722 0.846, 1.123
 Dependence with community activities of daily living 1.074 0.359 0.923, 1.249
 Comorbidities (up to 6, more than 6) 1.172 < 0.0001 1.073, 1.280
 Number of medications on admission 0.989 0.035 0.978, 0.999
 Total length of stay 1.004 < 0.0001 1.002, 1.006
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Geriatricians referred to multiple comorbidities leading 
to polypharmacy. Other challenges related to patient prob-
lems with medication adherence. Reasons for non-adherence 
related to adverse effects experienced by certain medica-
tions, and patients’ inability to swallow.
Discussion
The study provided comprehensive information about inap-
propriate prescribing in oldest old patients. The prevalence 
of having at least one PIM varied between 36.9% and 51.0% 
while the prevalence of having at least one PPO varied 
between 36.9% and 44.6% during patients’ hospitalisation. 
Use of mobility aids and an increasing number of medica-
tions on admission were associated with a higher incident 
count for PIMs. A higher comorbidity number and a longer 
length of hospital stay were associated with an increased 
incident count for PPOs. A higher number of medications 
on admission was associated with a reduced incidence rate 
of PPOs. Interviews with geriatricians identified many com-
plex challenges in prescribing medications for the oldest old, 
which related to medication characteristics, difficulties con-
fronting geriatricians, and concerns faced by patients.
Marked variability exists in determining PIMs in oldest 
old patients. Of the small number of studies undertaken in 
this population group, in community-dwelling people over 
3-year cycles (2003, 2007 and 2011), Ble et al. [15] found 
between 34.9% and 41.1% of patients aged 85 years and 
over had at least one PIM using Beers (2012 version), while 
Wauters et al. [16] found 56.1% of community-dwelling 
people aged 80 years and over had at least one PIM using 
STOPP (version 2). Using a translated version of the Beers 
criteria (2012), Lai et al. [17] showed, of patients aged 
80 years and over admitted to hospital, 27.1% had at least 
one PIM while San Jose et al. [18] found 63.3% of patients 
aged 85 years and over admitted to hospital had at least one 
PIM using the STOPP (version 2). The baseline level of 
at least one PIM (51.0%) was therefore similar to those of 
previous studies using the STOPP (version 2). In the cur-
rent study, the prevalence was shown to decrease to 36.9% 
during hospitalisation up to hospital discharge. Previous 
studies have been cross-sectional in nature while the cur-
rent study has been able to demonstrate downward trends 
in PIMs during patients’ hospitalisation. In geriatricians’ 
interviews, while there was recognition of the challenges 
involved in polypharmacy, they were cognisant of reducing 
inappropriate medication prescribing throughout patients’ 
hospitalisation.
The most common PIMs were the use of PPIs and ben-
zodiazepines. These findings are consistent with previous 
studies [19–26]. PPIs have been shown to be one of the most 
commonly prescribed medications in older people [27]. The 
standard General Practice management for patients with 
PPIs includes conducting frequent medication optimisation 
to reduce the dosage or cease PPIs if asymptomatic [27]. 
Despite these guidelines, active de-prescribing of PPIs is 
not necessarily practised [28, 29]. The complications associ-
ated with long-term use of PPIs include Clostridium difficile 
infections, hypomagnesaemia, renal disease, dementia and 
pneumonia [30].
Benzodiazepine use was also shown to be a major type 
of PIM identified. In the study cohort, benzodiazepine use 
was found to possibly contribute to the presence of adverse 
clinical outcomes, such as documented prolonged sedation, 
confusion, impaired balance, falls, dyspnoea, confusion, 
and reduced oxygen saturation. Although benzodiazepine 
use appeared to impact on adverse clinical outcomes, the 
prescription of this medication group decreased during hos-
pitalisation, which appeared to also be associated with a 
reduction in related adverse clinical outcomes. Past research 
has shown that oldest old patients who consumed benzo-
diazepines in hospital were more likely to have cognitive 
and psychomotor impairment compared with patients aged 
younger than 80 years [17]. Benzodiazepine use, especially 
for those prone to falls, was shown to be the most common 
cause of PIMs in the oldest old patients admitted to hospital 
[18].
The prevalence of having at least one PPO showed a 
downward trend for the four time points. If the omission of 
influenza and pneumococcal infections is included, the prev-
alence of at least one PPO ranged between 98.4% and 99.1%. 
There is a need for strategies and guidelines to improve the 
prescription of appropriate medications for the oldest old. 
In using the START (version 2), Wauters et al. [16] found a 
higher prevalence of 67.0% of at least one PPO in commu-
nity-dwelling people aged 80 years and over, while San José 
et al. [18] found 53.6% at least one PPO using START (ver-
sion 1). There are considerable differences between START 
version 1 and version 2. One of the most obvious is the 
presence of the two vaccinations relating to influenza and 
pneumococcal infections.
The most common PPO was vitamin D supplements, 
which is consistent with the findings of the few interna-
tional studies in the oldest old population [19–21]. Studies 
have shown that vitamin D supplements reduce the risk of 
fractures and falls [31, 32]. Given the high incidence of 
falls-related ED presentations and the subsequent morbid-
ity and mortality in this group, more vigilance is needed 
to ensure appropriate prescription of vitamin D supple-
ments. Thereafter, common PPOs were ACE inhibitors 
in patients with ischaemic heart disease or systolic heart 
failure and beta-blockers in patients with ischaemic heart 
disease, respectively, which have previously been identi-
fied as common PPOs in the oldest old [19–21]. One study 
reported that age > 75 years was an independent risk factor 
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for the under-prescription of ACE inhibitors and beta-
blockers [33]. Given that congestive cardiac failure was 
the most common primary diagnosis in this study sample, 
more steps need to be taken to prescribe medications such 
as ACE inhibitors and beta-blockers that have a proven 
mortality benefit [33].
Poisson regression results demonstrated that an increase 
in comorbidities was associated with an increased inci-
dent count in PPOs and with no effect on PIMs. The cur-
rent study involved calculation of comorbidity using the 
Charlson index, which may not be an accurate portrayal of 
how multimorbidity affects the oldest old. Development of 
a specific multimorbidity measurement for the oldest old 
would provide more appropriate measurement, which can be 
subsequently used to determine its associations with inap-
propriate prescribing.
Use of mobility aids was associated with an increased 
incident count of PIMs. Mobility aids comprised four-
wheel frames, two-wheel frames, single pronged sticks and 
crutches. Use of mobility aids was significantly linked with 
a history of falls. Many of these patients had also used long-
term benzodiazepines, which increase the prevalence of con-
fusion and dizziness.
There was a complex picture with the number of medi-
cations prescribed on admission, with a significant posi-
tive association involving the incident counts of PIMs and 
a significant negative association involving the incident 
counts of PPOs. Many studies have previously reported the 
positive association between the number of medications pre-
scribed and prevalence of PIMs [14, 21, 22, 24, 34]. With 
an increase in the number of medications, there could be a 
potential increase in the medication complexity regimen, 
leading to greater likelihood of adverse events and difficul-
ties in medication reconciliation [35]. Greater attention on 
medications known to improve therapeutic benefits in the 
oldest old while at the same time being cognisant of the 
adverse effects that are likely with other medications, would 
enable a more balanced approach to prescribing.
As the length of hospital stay increased, patients also 
experienced an increased prevalence for PPOs. As indicated 
by the geriatrician interviews, there was a focus on reduc-
ing polypharmacy as much as possible during the patients’ 
stay. This situation was evident by the number of PIMs that 
progressively reduced during patients’ hospitalisation. How-
ever, at the same time, there was little focus on attempting 
to commence appropriate medications that are warranted.
There were limitations relating to this study. For the 
STOPP criteria, patients were assumed to have been on a 
PPI for > 8 weeks. If possible, the long-term prescription 
of the medication was verified by checking discharge sum-
maries from other admissions or the medication list from 
the GP, to reduce the potential overestimation in the preva-
lence of PPI prescription. If no information was provided 
about the patients’ vaccination status, it was assumed that 
they did not have pneumococcal or influenza vaccination. 
Full adherence of patients with their medications was 
assumed. This was a single-centre study conducted in a 
tertiary teaching hospital with two sites, and the results 
cannot be generalised to other healthcare settings. The 
START and STOPP criteria do not capture the nuances 
of prescribing for patients on a case-by-case basis. While 
they are useful guides to safe prescribing, they are not 
substitutes for clinical reasoning.
This study demonstrated that oldest old patients are dis-
charged with high rates of PIMs and PPOs. Greater atten-
tion should be placed on actively de-prescribing medications 
that are not beneficial while simultaneously commencing 
medications that would be advantageous. Audits of a larger 
scale are needed to identify barriers to safe prescribing and 
implement steps towards improving prescribing practices for 
this vulnerable population.
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